AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34734199 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session group-based parenting programme
Number of subjects: 0
Study 34734199 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual services
Number of subjects: 0
Study 34734223 — intervention group
Group type: COMPARATOR
Intervention: Light drinkers (>2 to 10 g/d)
Number of subjects: 4365
Study 34734223 — intervention group
Group type: COMPARATOR
Intervention: Moderate drinkers (>10 to 30 g/d)
Number of subjects: 4365
Study 34734223 — intervention group
Group type: COMPARATOR
Intervention: Heavy drinkers (>30 g/d)
Number of subjects: 4365
Study 34734223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondrinkers (0 g/d) and very light drinkers (>0 to 2 g/d)
Number of subjects: 4365
Study 34734507 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-induced IL-22 releasing cells
Number of subjects: 27
Study 34734507 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-induced IFN-γ releasing cells
Number of subjects: 27
Study 34734507 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-induced GrB releasing cells
Number of subjects: 27
Study 34734507 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IFN-γ/IL-22/GrB ELISpot
Number of subjects: 27
Study 34734507 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-galactosylceramide supplementation
Number of subjects: 27
Study 34734825 — intervention group
Group type: EXPERIMENTAL
Intervention: Klondike Solitaire (played by participants living with MCI)
Number of subjects: 46
Study 34734825 — intervention group
Group type: COMPARATOR
Intervention: Klondike Solitaire (played by healthy participants)
Number of subjects: 46
Study 34734828 — intervention group
Group type: EXPERIMENTAL
Intervention: P3 app (Prepared, Protected, emPowered)
Number of subjects: 23
Study 34734828 — intervention group
Group type: EXPERIMENTAL
Intervention: P3 app adaptations
Number of subjects: 23
Study 34734828 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions (FGDs)
Number of subjects: 23
Study 34734828 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation process
Number of subjects: 23
Study 34734835 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 sessions of twice weekly EMDR plus treatment as usual
Number of subjects: 80
Study 34734835 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 80
Study 34734839 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-door screening and awareness generation activities in 8-12 villages surrounding the VCs.
Number of subjects: 2
Study 34734839 — intervention group
Group type: COMPARATOR
Intervention: Existing practices of awareness generation through community activities and health talks.
Number of subjects: 2
Study 34735517 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 144
Study 34735695 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic psycho-oncological adaptive screening (EPAS)
Number of subjects: 660
Study 34735860 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 200 mg twice daily as monotherapy
Number of subjects: 25
Study 34736130 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release buprenorphine injections (BUP-XR), administered monthly after a minimum of 7 days on 8-32 mg of sublingual buprenorphine (±naloxone)
Number of subjects: 100
Study 34736158 — intervention group
Group type: EXPERIMENTAL
Intervention: RBANS (Repeatable Battery for Assessment of Neuropsychological Status)
Number of subjects: 486
Study 34736158 — intervention group
Group type: EXPERIMENTAL
Intervention: PSP cognitive composite score
Number of subjects: 486
Study 34736497 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp nerve blocks with 0.5% bupivacaine plus dexamethasone (exact dosage not specified)
Number of subjects: 156
Study 34736497 — intervention group
Group type: COMPARATOR
Intervention: Scalp nerve blocks with 0.5% bupivacaine plus normal saline with epinephrine at 1:200,000
Number of subjects: 156
Study 34736503 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of ventilation tubes
Number of subjects: 45
Study 34736503 — intervention group
Group type: EXPERIMENTAL
Intervention: History of adenoidectomy
Number of subjects: 45
Study 34736503 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of hearing aids
Number of subjects: 45
Study 34736503 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing loss in at least one ear
Number of subjects: 45
Study 34736503 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing loss in youngest age group (16-44 years)
Number of subjects: 45
Study 34736503 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal tympanometry (Type B or C)
Number of subjects: 45
Study 34736503 — intervention group
Group type: EXPERIMENTAL
Intervention: Conductive hearing loss or combination of conductive and sensorineural hearing loss
Number of subjects: 45
Study 34736538 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiographic network analysis for personalized treatment targets
Number of subjects: 34
Study 34736538 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection methods for treatment targets
Number of subjects: 34
Study 34736561 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve replacement (TMVR)
Number of subjects: 100
Study 34736741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 0
Study 34736741 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34736789 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative soluble urokinase plasminogen activator receptor
Number of subjects: 0
Study 34736789 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative soluble urokinase plasminogen activator receptor between 5.5 and 10 ng/mL
Number of subjects: 0
Study 34736789 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative soluble urokinase plasminogen activator receptor >10 ng/mL
Number of subjects: 0
Study 34736789 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis of soluble urokinase plasminogen activator receptor
Number of subjects: 0
Study 34736789 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis combining age, sex, C-reactive protein levels, and American Society of Anesthesiologists score
Number of subjects: 0
Study 34736789 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding soluble urokinase plasminogen activator receptor to the model
Number of subjects: 0
Study 34736820 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE for Asthma
Number of subjects: 0
Study 34736820 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindstrong to Combat Bullying
Number of subjects: 0
Study 34737035 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently low hsCRP (hsCRP ≤ 2 mg/L)
Number of subjects: 1018
Study 34737035 — intervention group
Group type: EXPERIMENTAL
Intervention: Falling hsCRP (first high then low)
Number of subjects: 1018
Study 34737035 — intervention group
Group type: EXPERIMENTAL
Intervention: Rising hsCRP (first low then high)
Number of subjects: 1018
Study 34737035 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently high hsCRP (hsCRP > 2 mg/L)
Number of subjects: 1018
Study 34737791 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AFib)
Number of subjects: 0
Study 34737791 — intervention group
Group type: COMPARATOR
Intervention: Sinus rhythm (SR)
Number of subjects: 0
Study 34738049 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-cluster model
Number of subjects: 235
Study 34738090 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Ifosfamide, and Cisplatin (TIP)
Number of subjects: 19
Study 34738141 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-800CW (10 mg intravenously administered 3 days prior to surgery)
Number of subjects: 5
Study 34738141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence grid analysis
Number of subjects: 5
Study 34738141 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF-A as a target
Number of subjects: 5
Study 34738340 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (n = 68)
Number of subjects: 239
Study 34738340 — intervention group
Group type: COMPARATOR
Intervention: No sacubitril/valsartan (n = 164)
Number of subjects: 239
Study 34738853 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 measurement
Number of subjects: 0
Study 34739006 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation training using mechatronic shoes
Number of subjects: 35
Study 34739085 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34739137 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery in children with SARS-CoV-2 infection
Number of subjects: 0
Study 34739191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention using pharmacy refill data to monitor nonadherence and prompt discussions during clinic encounters.
Number of subjects: 130
Study 34739191 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider surveys measuring feasibility, acceptability, and appropriateness of the intervention.
Number of subjects: 130
Study 34739191 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient surveys measuring reactions to the intervention visit.
Number of subjects: 130
Study 34739334 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory prototyping of tailored U=U messaging developed in workshops
Number of subjects: 39
Study 34739527 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g Vitamin C 4 times a day during 4 days, started within 6 hours after admission
Number of subjects: 300
Study 34739527 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 300
Study 34739582 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin 3.2 mg/m
Number of subjects: 0
Study 34739844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus R-CHOP chemotherapy
Number of subjects: 2
Study 34739844 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP chemotherapy alone
Number of subjects: 2
Study 34740349 — intervention group
Group type: EXPERIMENTAL
Intervention: Family caregivers of critically ill adults with delirium
Number of subjects: 147
Study 34740593 — intervention group
Group type: EXPERIMENTAL
Intervention: Any respiratory symptom
Number of subjects: 4621
Study 34740593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough or phlegm
Number of subjects: 4621
Study 34740593 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheeze
Number of subjects: 4621
Study 34740593 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortness of breath
Number of subjects: 4621
Study 34740593 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest illnesses
Number of subjects: 4621
Study 34740593 — intervention group
Group type: COMPARATOR
Intervention: Zero vs three to four respiratory symptoms
Number of subjects: 4621
Study 34740742 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg/day)
Number of subjects: 362
Study 34740768 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage low-dose-rate (LDR) prostate brachytherapy (BT)
Number of subjects: 92
Study 34740876 — intervention group
Group type: EXPERIMENTAL
Intervention: EarlySense under-mattress device
Number of subjects: 76
Study 34740876 — intervention group
Group type: COMPARATOR
Intervention: Masimo Rad-97 pulse CO-oximeter with capnography reference device
Number of subjects: 76
Study 34740929 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban setting
Number of subjects: 200
Study 34740929 — intervention group
Group type: COMPARATOR
Intervention: Rural setting
Number of subjects: 200
Study 34740929 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual eye examinations and questionnaires
Number of subjects: 200
Study 34740986 — intervention group
Group type: EXPERIMENTAL
Intervention: Coiling
Number of subjects: 908
Study 34740986 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-assisted coiling (BAC)
Number of subjects: 908
Study 34740986 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 908
Study 34740986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruptured aneurysms
Number of subjects: 908
Study 34740986 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm size ≥10 mm
Number of subjects: 908
Study 34740986 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide neck aneurysms
Number of subjects: 908
Study 34740986 — intervention group
Group type: EXPERIMENTAL
Intervention: MCA location
Number of subjects: 908
Study 34741021 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine (T-DM1)
Number of subjects: 0
Study 34741021 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine/pertuzumab
Number of subjects: 0
Study 34741021 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab/paclitaxel
Number of subjects: 0
Study 34741102 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral sildenafil (cohort 1)
Number of subjects: 32
Study 34741102 — intervention group
Group type: EXPERIMENTAL
Intervention: IV sildenafil 0.25 mg/kg (cohort 2)
Number of subjects: 32
Study 34741102 — intervention group
Group type: EXPERIMENTAL
Intervention: IV sildenafil 0.125 mg/kg (cohort 2)
Number of subjects: 32
Study 34741172 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPA-AREG (medium with amphiregulin 100 ng/ml)
Number of subjects: 30
Study 34741172 — intervention group
Group type: COMPARATOR
Intervention: CAPA-Control (medium without amphiregulin)
Number of subjects: 30
Study 34741189 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment limitations
Number of subjects: 0
Study 34741240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Number of subjects: 264
Study 34741240 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 264
Study 34741240 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 264
Study 34741321 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcortical miniscrew placed over the buccal plate of the extraction socket
Number of subjects: 6
Study 34741321 — intervention group
Group type: COMPARATOR
Intervention: Control side (untreated extraction socket)
Number of subjects: 6
Study 34741536 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation (CR)
Number of subjects: 23430
Study 34741779 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education intervention for parents, consisting of two workshops of 2 hours each.
Number of subjects: 70
Study 34741779 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no intervention).
Number of subjects: 70
Study 34741794 — intervention group
Group type: EXPERIMENTAL
Intervention: Arcing stroke pattern
Number of subjects: 40
Study 34741794 — intervention group
Group type: EXPERIMENTAL
Intervention: Semicircular (SC) stroke pattern
Number of subjects: 40
Study 34741794 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-loop (SL) stroke pattern
Number of subjects: 40
Study 34741794 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-loop (DL) stroke pattern
Number of subjects: 40
Study 34741822 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 sequelae
Number of subjects: 2634
Study 34741822 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent treatment discontinuation
Number of subjects: 2634
Study 34741822 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose or regimen adjustment
Number of subjects: 2634
Study 34741932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dual task (CDT)
Number of subjects: 53
Study 34741932 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor dual task (MDT)
Number of subjects: 53
Study 34741932 — intervention group
Group type: COMPARATOR
Intervention: Single task (ST)
Number of subjects: 53
Study 34742157 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 SARS-CoV-2 vaccination (two doses)
Number of subjects: 291
Study 34742157 — intervention group
Group type: COMPARATOR
Intervention: Active surveillance (control group)
Number of subjects: 291
Study 34742314 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimpanzees profile (high-MPA, low-inactivity, average-night-sleep)
Number of subjects: 442
Study 34742314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandas profile (low-PA, high-inactivity, high-night-sleep)
Number of subjects: 442
Study 34742314 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbits profile (very high-MPA/VPA, low-inactivity, average-night-sleep)
Number of subjects: 442
Study 34742325 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 360
Study 34742325 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai ji quan training
Number of subjects: 360
Study 34742325 — intervention group
Group type: COMPARATOR
Intervention: Stretching (control)
Number of subjects: 360
Study 34742327 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced/buffered crystalloids
Number of subjects: 8800
Study 34742327 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 8800
Study 34742328 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week resistance training program focusing on proximal and knee muscles using power and strength exercises
Number of subjects: 74
Study 34742328 — intervention group
Group type: COMPARATOR
Intervention: 12-week resistance training program focusing on proximal and knee muscles using strength exercises only
Number of subjects: 74
Study 34742578 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance olaparib
Number of subjects: 289
Study 34742578 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor BRCA testing
Number of subjects: 289
Study 34742578 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 289
Study 34743035 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting < 6 hours
Number of subjects: 100
Study 34743035 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting ≥ 6 hours
Number of subjects: 100
Study 34743035 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) within the last 48 hours
Number of subjects: 100
Study 34743035 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of enteral nutrition (EN)
Number of subjects: 100
Study 34743540 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 5034
Study 34743549 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement (AVR)
Number of subjects: 33018
Study 34743551 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 5648
Study 34743551 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 5648
Study 34743551 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 5648
Study 34743565 — intervention group
Group type: EXPERIMENTAL
Intervention: RISTRA-ACS (risk stratification for acute coronary syndrome) implemented in 13 EDs
Number of subjects: 154914
Study 34743565 — intervention group
Group type: COMPARATOR
Intervention: Control sites (8 EDs without RISTRA-ACS)
Number of subjects: 154914
Study 34743701 — intervention group
Group type: EXPERIMENTAL
Intervention: eM2M intervention (12-week remotely delivered rhythmic exercise program)
Number of subjects: 108
Study 34743729 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD depressed patients (CD, n=27)
Number of subjects: 78
Study 34743729 — intervention group
Group type: COMPARATOR
Intervention: COPD patients without depression (not explicitly mentioned in the abstract)
Number of subjects: 78
Study 34743734 — intervention group
Group type: EXPERIMENTAL
Intervention: High homocysteine levels (highest tertile)
Number of subjects: 175
Study 34743734 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with dNCR
Number of subjects: 175
Study 34744427 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast (ROF)
Number of subjects: 38
Study 34744427 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 38
Study 34744669 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated position interlimb coordination performance assessment
Number of subjects: 0
Study 34744766 — intervention group
Group type: EXPERIMENTAL
Intervention: Different levels of variability in pressure support ventilation
Number of subjects: 0
Study 34744766 — intervention group
Group type: COMPARATOR
Intervention: Standard pressure support ventilation
Number of subjects: 0
Study 34744825 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 0
Study 34744918 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful-Compassion Art-based Therapy (MCAT), a 6-week, 18-hours intervention
Number of subjects: 56
Study 34744918 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 56
Study 34744972 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34744989 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34745093 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa (inhaled)
Number of subjects: 0
Study 34745093 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 34745199 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal plasma lipid concentrations
Number of subjects: 64
Study 34745199 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental gene co-expression network analysis
Number of subjects: 64
Study 34746196 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related hearing loss with tinnitus and physical frailty
Number of subjects: 0
Study 34746207 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 0
Study 34746207 — intervention group
Group type: COMPARATOR
Intervention: Infliximab treatment without Vitamin D3 supplementation
Number of subjects: 0
Study 34746252 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking activity
Number of subjects: 0
Study 34746252 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 34746258 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin
Number of subjects: 0
Study 34746258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34746424 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized blood pressure management (maintaining systolic blood pressure at the level on presentation ±10 mmHg)
Number of subjects: 0